Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Nat Rev Drug Discov. 2016 Nov 3;16(3):181–202. doi: 10.1038/nrd.2016.199

Table 3.

Key companies in the global aptamers market

Company name Founded/location Focus and exclusive technology Featured products and services
NOXXON Pharma AG 1997/Berlin, Germany Therapeutics development:
Mirror-image chemistry/Spiegelmer® (RNA or DNA-L-stereoisomer) -based therapeutics for cancer, inflammation, obesity or other diseases.

  • In the clinical pipeline: NOX-A12 (CXCL12/SDF-1); NOX-36 (CCL2); NOX-H94 (Hepcidin);

  • In the preclinical pipeline: NOX-S93 (S1P); NOX-D21 (C5a); NOX-G16 (Glucagon); NOX-L41 (CGRP)
Ophthotech Corp. 2007/New York, USA Therapeutics development:
Modified RNA or DNA aptamer therapeutics for eye diseases:

  • In the clinical pipeline: Zimura® (C5); Fovista® (PDGF)
Archemix
(acquired by Baxter in 2010)		 2000/San Francisco, USA Therapeutics development:
Modified RNA or DNA aptamers therapeutics for cardiovascular, hematology, and oncology diseases.

  • In the clinical pipeline: ARC1779 (von Willebrand factor) ARC19799 (TFPI)
NeXstar (merged with Gilead) 1999/Boulder, Colorado, USA Therapeutics development:
SELEX license/Modified RNA or DNA aptamers therapeutics for transplant rejection and other immunological responses and aptamer-based diagnostics

  • In the preclinical pipeline: G-quadruplex-bearing DNA aptamer (thrombin); HD22 (thrombin exosite II)
SomaLogic 1999/Boulder, Colorado, USA Diagnostics development:
SOMAmer (Slow Off-rate Modified Aptamer) for diagnosis and proteomic analysis;

  • SOMAscan (large groups of SOMAmer for protein biomarker discovery and diagnosis);

  • SOMAmer reagents (therapeutics, quantitative analysis, affinity purification, flow cytometry, etc.);

  • SOMApanels (smaller groups of SOMAmers for qualitative or quantitative analysis);

  • SOMAsuite (professional software tool for proteomic data analysis)

  • SOMAmer discovery service (proteomics service)
NeoVentures 2002/Ontario, Canada R & D support and diagnostics development:
Custom aptamer identification; diagnostics development for detecting toxins in wine, corn, beer and wheat.

  • Aptamer selection (including next generation sequencing analysis);

  • Aptamer trimming and characterization (binding affinity, SPR, interaction analysis);

  • ELASA/ELISA development;

  • UltraFast affinity columns for HPLC clean-up
AptaMatrix 2003/New York, USA R & D support and diagnostics development:
High throughput screening of aptamers (HTSA); diagnostics development

  • Rapid aptamer selection via HTSA

  • AlloSwith (aptamer-based biosensor for real-time detection)
Aptamer Solutions (Aptasol) 2008/York, United Kingdom R & D support and diagnostics development:
Automated high throughput selection systems; Custom aptamer identification; diagnostics and biomarker development

  • High throughput aptamer isolation, characterization and validation;

  • High throughput antibody replacement (HARP);

  • R&D consumables (from fluorescent microscopy, flow cytometry probes to purification reagents);

  • Aptamer-based assay development
Aptus Biotech 2010/Madrid, Spain R & D support and diagnostics development:
Custom aptamer identification; aptamer; diagnostics development

  • >20 aptamers in the catalog;

  • Aptamer isolation, trimming, characterization and validation;

  • Aptamer-based assay development
Aptagen 2004/Jacobus, Pennsylvania, USA R & D support and diagnostics development:
Custom aptamer identification; aptamer products and aptamer database

  • Aptamer selection (including whole animal selection by using animal model of disease or condition);

  • Apta-Index (aptamer database);

  • Apta-sensors (molecular beacon aptamer for diagnostic assay);
Aptamer Sciences (AptaSci) 2011/Pohang, South Korea R & D support:
Custom aptamer identification; aptamer products;

  • >200 aptamers in the catalog;

  • Aptamer selection, modification and characterization;

  • Aptamer-based assay development (isolation, ELASA)
AM Biotechnologies 2006/Houston, Texas, USA R & D support:
X-aptamer technology; Thioaptamers (based on phosphorodithioate (PS2) DNA)

  • Custom X-aptamer identification (including synthesis, modification and functional evaluation);

  • X-aptamer isolation kit (microbead-based X-aptamer selection);
Vivonics 2012/Sudbury, Massachusetts, USA R & D support:
One-step rapid technique for developing aptamers (RIDA)

  • Rapid isolation of DNA aptamer (RIDA) by HPLC
TriLink 1996/San Diego, California, USA R & D support:
Solid-phase chemical synthesis of RNA and DNA

  • Aptamer synthesis, modification and conjugation

  • Random libraries and primers
HHS Vulnerability Disclosure